Mumbai: Dilip Shanghvi, founder of Sun Pharmaceutical, recently announced the company's acquisition of Organon & Co. for $11.75 billion. This deal is poised to double Sun's revenue to $12.4 billion, a significant milestone for the Indian pharmaceutical giant.
Shanghvi expressed a mix of emotions at the press conference, reflecting on the magnitude of the transaction, which he likened to the Ranbaxy Laboratories acquisition a decade ago. This time, however, Sun is acquiring a company of similar size, utilizing cash and borrowed funds rather than stock.
Shifting Strategies
The Organon acquisition is not merely about expanding scale; it represents a strategic pivot away from the saturated US generics market. Sun Pharma aims to enhance its presence in China and biosimilars, areas that have long been on its radar.
Aalok Shanghvi, Dilip's son and the newly appointed COO, is central to this vision. Having spent over two decades building Sun's international business, Aalok's leadership is expected to drive the company's future growth.
The Decline of US Revenue
Sun Pharma's US operations once accounted for 60% of its revenue, but this has drastically changed. The company’s revenue in the US peaked at $2.24 billion in FY15 but fell to $1.92 billion by FY25 due to increased competition and pricing pressures from large pharmacy chains and benefit managers.
Despite investments in specialty medicines helping to stabilize revenue, the overall trend has been a decline, prompting Sun to seek new markets for growth.
Aalok's Journey
Aalok Shanghvi's path within Sun Pharma has been distinct from his father's. Known for his low-profile approach, Aalok has focused on results rather than media attention. His experience in emerging markets has been pivotal, especially after the Ranbaxy merger, which expanded Sun's international footprint.
Under his leadership, the emerging markets segment has seen significant growth, crossing $1 billion in revenue by FY24, demonstrating the effectiveness of his strategies.
What the Organon Acquisition Brings
Organon, spun off from Merck, has a diverse portfolio including women's health products, established brands, and biosimilars. While it has struggled with growth, it offers Sun a robust global platform in 140 countries, a strong presence in China, and a solid biosimilar infrastructure.
This acquisition is expected to enhance Sun's distribution capabilities and provide a foundation for future product launches, particularly in the burgeoning Chinese market.
Market Reactions
Analysts have responded positively to the acquisition, viewing it as a strategic fit that could transform Sun's growth trajectory. Brokerages have noted the deal's potential to leverage Organon's infrastructure for broader market penetration.
However, concerns remain regarding Organon's stagnant growth and its debt burden, which Sun aims to address through refinancing strategies.
Succession Planning
The timing of Aalok's elevation to COO and the scale of the Organon deal signal a clear succession plan. Dilip Shanghvi, now 70, acknowledges the importance of involving his family in major decisions, indicating a thoughtful transition of leadership.
By investing heavily in a business segment that aligns with Aalok's expertise, Dilip is not just pursuing growth but also establishing a legacy for the next generation.
Future Outlook
As the global generics industry faces challenges, Sun Pharma's approach stands out. With a focus on geographic diversity and brand equity, the company is well-positioned to navigate the evolving landscape.
Post-acquisition, emerging markets will contribute significantly to Sun's revenue, reflecting a strategic shift away from dependence on the US market.
The next decade will be crucial for Aalok Shanghvi as he steps into a leadership role that could redefine Sun Pharma's global ambitions.
